OncoMatch/Clinical Trials/NCT06176729

Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients

Is NCT06176729 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Polatuzumab Vedotin, Rituximab, Lenalidomide for diffuse large b cell lymphoma.

Phase 2RecruitingYan Zhang, MDNCT06176729Data as of May 2026

Treatment: Polatuzumab Vedotin, Rituximab, Lenalidomide — This is a prospective, single-arm, phase II study, and the purpose of this study is to evaluate the efficacy and safety of Pola-R2 regimen in newly diagnosed elderly diffuse large B cell lymphoma classified into un-fit or frail group by comprehensive geriatric assessment(CGA).

Check if I qualify

Extracted eligibility criteria

Cancer type

Diffuse Large B-Cell Lymphoma

Non-Hodgkin Lymphoma

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Lab requirements

Blood counts

adequate bone marrow reserve

Kidney function

adequate organ function

Liver function

adequate organ function

Adequate organ function and adequate bone marrow reserve

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify